Sculptra is approved in the United States. Hyacorp is not. Hyacorp is a hyaluronic acid gel made by BioScience GmbH in Germany. It is sold in Europe and other CE-marked countries for body contouring: buttocks, hips, calves and pectorals. It holds no US FDA approval and no US FDA clearance. Sculptra is approved through the FDA's premarket approval route, PMA P030050, for named facial indications.
They also work in opposite ways. Hyacorp is a hyaluronic acid gel. It takes up space, so the volume is there as soon as it is injected. Sculptra is poly-L-lactic acid, or PLLA. These are tiny particles that provoke the body into laying down its own collagen over the following weeks and months. Nothing looks fuller on the day Sculptra goes in.
The reversibility difference runs the opposite way to what most people expect. Hyacorp is hyaluronic acid, so hyaluronidase breaks it down. Sculptra is a polyester of lactic acid. Hyaluronidase does nothing to it. There is no approved reversal agent for PLLA.
For a US reader the practical answer is short. Sculptra's approvals are facial only. So using it on the body is off-label, which is legal and routine. Hyacorp sits outside the US regulatory framework entirely. No US agency has reviewed its evidence, its manufacturing or its labelling. The FDA also states plainly that it "recommends against using dermal fillers or any injectable filler for body contouring and enhancement." It names breast augmentation, increasing the size of the buttocks and increasing fullness of the feet.
The MLF1 and MLF2 products are the body range.
Freeze-dried PLLA particles mixed with sterile water shortly before injection.
It is marketed in Europe and other territories that accept CE marking.
The original 2004 approval was for "restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with or receiving treatment for human immunodeficiency virus." Cosmetic indications came later: 2009 for nasolabial folds and other facial wrinkles, and 2023 for fine lines and wrinkles in the cheek region.
PLLA is also injected on the body, and that use is off-label. Off-label use is legal and routine.
This is why it is called a biostimulator rather than a filler.
Do not let a body filler be lumped in with the biostimulators on this point. Being hyaluronic acid is its real advantage.
If a result is unwanted the options are time, saline injection with mechanical disruption, steroid injection and, rarely, surgery.
There is no FDA summary of safety and effectiveness to read for this product.
The 2023 cheek trial randomised 149 people at 13 US sites against no treatment: 70.7% responders at month 12 against 25.9%. Off-face use of poly-L-lactic acid has published real-world safety data but no registration trial.
A product with no US approval or clearance sits outside the US framework, so a US clinic offering it is injecting something the FDA has never reviewed.
It does not mean the product has been tested and rejected. It means no application was made. No US regulator has looked at it. For someone in the United States, three things follow.
There is no FDA-reviewed evidence file to read: Approved fillers come with a public summary of safety and effectiveness. It sets out how many people were studied, what was measured and what went wrong. There is nothing equivalent for a product that never entered the process.
There is no approved indication, so there is no such thing as on-label use: With Sculptra you can at least read the exact wording of what it was approved to treat. Then you can see how far a proposed treatment sits from it.
Supply is not overseen by the FDA: Products sold into US clinics outside the approval framework reach them through channels the agency does not inspect. That is a separate question from whether the material itself is any good.
None of this is an accusation. It is the boundary of what can be verified.
The usual shorthand is that newer products are safer because they are less permanent. Here the shorthand fails. Hyacorp, despite being unapproved in the US, is hyaluronic acid, and hyaluronidase breaks hyaluronic acid down. Sculptra, despite being FDA-approved and long established, is not reversible at all - hyaluronidase has no chemical target in poly-L-lactic acid, and the Sculptra instructions for use contain no statement about a reversal agent because there is none.
That matters most in an emergency. If filler blocks an artery, dissolving hyaluronic acid is the standard response. There is no equivalent step for PLLA, which is why prevention and injector experience carry more weight with a biostimulator.
Body work of any kind uses far more material than facial work, and volume is a risk factor in itself. That is part of why the FDA's advice against injectable fillers for buttock and breast enhancement exists as a standing statement, and it applies to any filler used that way, approved or not.
There is also a simpler point. A gel and a biostimulator are not interchangeable choices for the same goal. If the goal is a visible shape change on the day, a collagen stimulator will disappoint. If the goal is a gradual, subtler build in tissue quality and fullness, a gel is doing something different. Deciding which problem you have comes before deciding which product.
Sudden change or loss of vision
Sudden severe pain, or pain out of proportion to the injection
Skin turning white or pale, then dusky, blotchy or mottled
Drooping on one side of the face, weakness in an arm or leg, or trouble speaking
These can mean filler has entered an artery. Time matters in hours.
Swelling keeps increasing after the first few days instead of settling
A lump appears and will not settle, or one appears weeks or months later
Redness is spreading around the injection site, or you develop a fever
Tenderness or firmness appears weeks after treatment
The material appears to have moved from where it was placed